Skip to content
naulon
Get started

Not checked for notices yet.

Elevated IFNA1 and suppressed IL12p40 associated with persistent hyperinflammation in COVID-19 pneumonia

Kyeongseok Jeon, Kyeongseok Jeon, Yuri Kim and 36 more

Frontiers in Immunology · 2023

doi:10.3389/fimmu.2023.1101808

References 51

  1. 1.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  2. 2.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  3. 3.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  4. 4.
    Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool · 2013
    No notice
  5. 5.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  6. 6.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  7. 7.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  8. 8.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  9. 9.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  10. 10.
    Massively parallel digital transcriptional profiling of single cells · 2017
    No notice
  11. 11.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  12. 12.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  13. 13.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  14. 14.
    Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection · 2020
    No notice
  15. 15.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  16. 16.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  17. 17.
    Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans · 2020
    No notice
  18. 18.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  19. 19.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  20. 20.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  21. 21.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  22. 22.
    An immune-based biomarker signature is associated with mortality in COVID-19 patients · 2021
    No notice
  23. 23.
    The Gene Ontology resource: enriching a GOld mine · 2020
    No notice
  24. 24.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  25. 25.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  26. 26.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  27. 27.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  28. 28.
    Type I and III interferon responses in SARS-CoV-2 infection · 2021
    No notice
  29. 29.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  30. 30.
    Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection · 2021
    No notice
  31. 31.
    Integrated analysis of multimodal single-cell data · 2021
    No notice
  32. 32.
    SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care · 2021
    No notice
  33. 33.
    A time-resolved proteomic and prognostic map of COVID-19 · 2021
    No notice
  34. 34.
    High‐resolution serum proteome trajectories in COVID‐19 reveal patient‐specific seroconversion · 2021
    No notice
  35. 35.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  36. 36.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  37. 37.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  38. 38.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  39. 39.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  40. 40.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  41. 41.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  42. 42.
    The relationship between COVID‐19 viral load and disease severity: A systematic review · 2021
    No notice
  43. 43.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  44. 44.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  45. 45.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  46. 46.
    T cell apoptosis characterizes severe Covid-19 disease · 2022
    No notice
  47. 47.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  48. 48.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  49. 49.
    COVID-19 therapeutics: Challenges and directions for the future · 2022
    No notice
  50. 50.
    Long COVID after breakthrough SARS-CoV-2 infection · 2022
    No notice
  51. 51.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.